Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

Creative Commons License

ÖZGÜROĞLU M., Levy B., Horinouchi H., Yu J., Grainger E., Phuong P., ...More

ANNALS OF ONCOLOGY, vol.33, no.7, 2022 (SCI-Expanded) identifier

  • Publication Type: Article / Abstract
  • Volume: 33 Issue: 7
  • Publication Date: 2022
  • Doi Number: 10.1016/j.annonc.2022.07.1097
  • Journal Name: ANNALS OF ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
  • Istanbul University Affiliated: No